In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology.
Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes by reflecting on BTOG 2025’s success and NHS England’s new service specification.
